healthandpharma20h
Verseon's New AI Model VersAI™ Elevates AI Accuracy in Drug Discovery with Sparse Data
Verseon International Corporation has announced that its noval AI technology, VersAI™, demonstrates superior prediction ...
healthandpharma2d
ESMO 2024: BRAFTOVI and MEKTOVI Extend Survival in Aggressive BRAF V600E-Mutant Lung Cancer
Pfizer announced that its combination therapy of BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) has demonstrated ...
healthandpharma3d
Presented at ESMO 2024: Novartis's Kisqali Reduces Breast Cancer Recurrence Risk by 28.5%
The latest data from the Phase III NATALEE trial, presented at ESMO 2024, demonstrate that adding Kisqali (ribociclib) to standard endocrine therapy reduces the risk of breast cancer recurrence by ...
healthandpharma7d
The OVATION 2 Study and the Novel Immunotherapy IMNN-001 for Ovarian Cancer
We welcomed two special guests, Dr. Stacy Lindborg, CEO of IMUNON, and Dr. Premal Thaker, Gynecologic Oncologist at Washington University, to discuss the results of the OVATION 2 Study and the latest ...